SANTA CRUZ BIOTECHNOLOGY, INC.

p-p53 (Thr 55)-R: sc-12904-R



BACKGROUND

p53 is a DNA-binding, oligomerization domain- and transcription activation domain-containing tumor suppressor that upregulates growth arrest and apoptosis-related genes in response to stress signals, thereby influencing programmed cell death, cell differentiation and cell cycle control mechanisms. p53 localizes to the nucleus yet can be chaperoned to the cytoplasm by the negative regulator MDM2, an E3 ubiquitin ligase that is upregulated in the presence of active p53, where MDM2 polyubiquitinates p53 for proteasome targeting. p53 can assemble into tetramers in the absence of DNA, fluctuates between latent and active (DNA-binding) conformations, and is differentially activated through posttranslational modifications including phosphorylation and acetylation. Mutations in the DNA-binding domain (DBD) (amino acids 110-286) of p53 can compromise energetically favorable association with *cis* elements and are implicated in several human cancers. Phosphorylation of p53 at residue Thr 155 is mediated by the COP9 signalosome (CSN) and targets p53 to ubiquitin-26S Proteasome-dependent degradation.

CHROMOSOMAL LOCATION

Genetic locus: TP53 (human) mapping to 17p13.1.

SOURCE

p-p53 (Thr 55)-R is an affinity purified rabbit polyclonal antibody raised against a short amino acid sequence containing Thr 55 phosphorylated p53 of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-12904 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

APPLICATIONS

p-p53 (Thr 55)-R is recommended for detection of Thr 55 phosphorylated p53 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for p53 siRNA (h): sc-29435, p53 shRNA Plasmid (h): sc-29435-SH and p53 shRNA (h) Lentiviral Particles: sc-29435-V.


Molecular Weight of p-p53: 53 kDa.


Positive Controls: A-431 whole cell lysate: sc-2201, MCF7 + etoposide cell lysate: sc-2281 or A-431+PMA cell lysate: sc-2261.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker[™] compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker[™] Molecular Weight Standards: sc-2035, TBS Blotto B Blocking Reagent: sc-2333, Western Blotting Luminol Reagent: sc-2048 and Lambda Phosphatase: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz[™] Mounting Medium: sc-24941. 4) Immunohistochemistry: use ImmunoCruz[™]: sc-2051 or ABC: sc-2018 rabbit IgG Staining Systems.

DATA





Western blot analysis of p53 phosphorylation in untreated (A,D), ERK2 treated (B,E) and ERK2 and lambda protein phosphatase (sc=200312A) treated (C,F) human recombinant p53. Antibodies tested include p-p53 (Thr 55)-R: sc=12904-R: (A,B,C) and p53 (Pba 240): sc=99 (D, E, F). p-p53 (Thr 55)-R: sc-12904-R. Immunoper-oxidase staining of formalin fixed, paraffin-embedded human oral mucosa tissue showing nuclear staining of subset of squamous epithelial cells.

SELECT PRODUCT CITATIONS

- Yeh, P.Y., et al. 2004. Phosphorylation of p53 on Thr55 by ERK 2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 23: 3580-3588.
- Xia, L., et al. 2004. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14 ARF. Cancer Res. 64: 221-228.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

MONOS Satisfation Guaranteed Try p-p53 (B-3): sc-377553, our highly recommended monoclonal aternative to p-p53 (Thr 55).

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com